GlassScriptPhysician profile
Mehmet Cilingiroglu
NPI 1710922125
$3,396.25
in general payments reported to CMS, 2019-2025
14 companies · $47.51 in 2025
The $47.51 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $109 · 2021: $141 · 2022: $2,554 · 2023: $117 · 2024: $70.54 · 2025: $47.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,383.39 | 2021-2022 | |
| Medtronic, INC. | $1,377.55 | 2022-2023 | Micra |
| Cook Medical LLC | $117.22 | 2019 | |
| Corindus INC. | $109.43 | 2019 | |
| Biotronik INC. | $108.54 | 2020 | |
| Boston Scientific Corporation | $106.62 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.51 | 2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $47.51 | 2025 | |
| Scpharmaceuticals INC. | $27.31 | 2024 | |
| Medtronic Vascular, INC. | $24.94 | 2019 | |
| Pfizer INC. | $22.46 | 2024 | |
| Philips North America LLC | $20.77 | 2024 | (Ck4) Mcot |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehmet Cilingiroglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.